a 19-year-old man
Refractory immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN)
A 19-year-old man had immune complex membranoproliferative glomerulonephritis. He came in with heavy protein in his urine, blood in his urine, low blood albumin (20 g/L), and low complement (C3 as low as 0.06 g/L). A kidney biopsy confirmed the diagnosis. Steroids and tacrolimus did not control the disease, so his doctors started pegcetacoplan, a C3 blocker, at 1,080 mg injected under the skin twice a week. His urine protein-to-creatinine ratio fell to 751 mg/g, down 70 percent, and his 24-hour urine protein fell to 1,386 mg a day, down 83 percent. His blood albumin rose from 20 to 36 g/L and his creatinine stayed stable at 92 micromol/L. His complement returned to normal, with C3 rising from 0.06 to 1.27 g/L, and he was able to stop his blood pressure and immune-suppressing drugs. No side effects were seen.
In one young man whose immune-complex MPGN kept flaring despite steroids and tacrolimus, adding the C3 blocker pegcetacoplan brought a fast, large drop in urine protein and returned his complement and albumin to normal.
- His disease was refractory, meaning standard immune-suppressing drugs (corticosteroids and tacrolimus) did not control it before pegcetacoplan was started.
- After pegcetacoplan, his urine protein-to-creatinine ratio fell to 751 mg/g, a 70 percent drop, and his 24-hour urine protein fell to 1,386 mg/day, an 83 percent drop.
- His blood albumin rose from 20 to 36 g/L and his complement C3 climbed from 0.06 g/L back up to a normal 1.27 g/L.
- His kidney function held steady, with serum creatinine unchanged at 92 micromol/L, and no adverse events were reported.
- The improvement was strong enough that his doctors were able to stop his blood pressure and immune-suppressing medications.
Why it might work
IC-MPGN is driven in part by an overactive branch of the immune system called the alternative complement pathway. When this pathway runs unchecked, it damages the tiny filters in the kidney, which lets protein leak into the urine and drives down the C3 complement protein in the blood. Pegcetacoplan blocks C3, a central hub in that pathway, so the paper's reasoning is that shutting down C3 stops the ongoing filter damage at its source. That fits what happened here: as C3 was blocked, the urine protein dropped sharply and the blood levels of C3 and albumin returned to normal.
The honest limits
- This is a single case (n=1), so it cannot tell us how often pegcetacoplan works or in whom; one person improving is not proof for a group.
- This was a short report, and the authors themselves note that longer follow-up is needed to know if the benefit lasts.
- The abstract does not report how long the patient was treated or followed, nor whether a repeat biopsy confirmed the kidney tissue actually healed.
- The abstract does not state whether the authors had any financial ties to the drug's maker, so a reader cannot rule out a conflict of interest from this text alone.
- Is my type of glomerulonephritis one where the alternative complement pathway is overactive, and would checking my C3 level help tell?
- Given that this is based on a single case, what is known about the risks and long-term safety of a C3 blocker like pegcetacoplan?
- If my current immune-suppressing drugs are not controlling my protein levels, are complement-targeted treatments something I could be evaluated for?